1. Scrip
  2. >>Therapy Areas

Trophos to file olesoxime after positive data in orphan indication

 
• By Gemma Collier

French pharma Trophos has reported positive top-line data from its pivotal Phase II/III study of olesoxime in spinal muscular atrophy (SMA), a product the company has resolutely backed despite past setbacks.

French pharma Trophos has reported positive top-line data from its pivotal Phase II/III study of olesoxime in spinal muscular atrophy (SMA), a product the company has resolutely backed despite past setbacks.

Olesoxime, a cholesterol-like compound that targets and preserves mitochondrial integrity and function in stressed cells, was shown to prevent loss...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapy Areas

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.